Vaxart Provides Business Update and Reports Third Quarter 2026 Financial Results

Research spending fell, but lower quarterly revenue accompanied a wider loss; cash runway is expected into the second quarter of 2027.

Rhea-AI Summary

Vaxart (OTCQX: VXRT) reported third-quarter 2026 revenue of $10.620 million, alongside a wider net loss and updated vaccine development timelines. Revenue fell from $72.413 million a year earlier, while net loss widened to $17.689 million from $8.141 million. Loss per share was $0.07 versus $0.04.

Cash, cash equivalents and short-term investments totaled $65.5 million at September 30, 2026; the company expects its cash runway to extend into the second quarter of 2027. Vaxart expects Phase 2b COVID-19 efficacy and safety results by mid-year 2027, covering 400 sentinel safety participants and approximately 5,000 main-cohort participants. Cumulative BARDA contract cash payments reached $278.0 million. A new European norovirus vaccine patent extends protection through at least 2036. VXA-H5-02 showed complete protection against a fatal dose of the current dominant H5N1 strain in a preclinical study. Raquel Bono joined the board in October.

10 points · 0 major

MixediHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

1 major · 9 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Moderate pointResearch and development expenses fell to $22.829 million in Q3 2026 from $75.947 million a year earlier.
• Moderate pointNine-month net loss narrowed to $26.004 million, or $0.11 per share, from $38.718 million, or $0.17.
• Moderate pointBARDA contract cumulative cash payments reached $278.0 million as of September 30, 2026. 2.9× market cap
• Moderate point. Forward-looking: it has not happened yet and may not happen.Vaxart expects complete Phase 2b COVID-19 efficacy and safety results by mid-year 2027.
• Moderate pointTotal liabilities declined to $81.888 million at September 30, 2026, from $98.281 million at December 31, 2025.

5 minor points

• Minor pointNine-month research and development expenses fell to $85.996 million in 2026 from $156.426 million in 2025.
• Minor pointNine-month operating loss narrowed to $25.282 million in 2026 from $37.349 million in 2025.
• Minor pointEuropean norovirus vaccine patent extends intellectual property protection through at least 2036 across major European jurisdictions.
• Minor pointVXA-H5-02 demonstrated complete protection against a fatal dose of the current dominant H5N1 strain in preclinical testing.
• Minor pointVaxart is exploring business development partnerships and non-dilutive funding to extend cash runway.

Negative

• Major pointQ3 2026 revenue fell to $10.620 million from $72.413 million a year earlier.
• Moderate pointQ3 2026 net loss widened to $17.689 million, or $0.07 per share, from $8.141 million, or $0.04.
• Moderate point. Forward-looking: it has not happened yet and may not happen.Cash runway is expected to extend into only the second quarter of 2027.
• Moderate pointStockholders’ equity declined to $66.293 million at September 30, 2026, from $87.798 million at December 31, 2025.
• Moderate pointTotal assets declined to $148.181 million at September 30, 2026, from $186.079 million at December 31, 2025.

4 minor points

• Minor pointQ3 2026 operating loss widened to $17.283 million from $7.811 million a year earlier.
• Minor pointNine-month revenue declined to $77.032 million in 2026 from $133.019 million in 2025.
• Minor pointQ3 2026 general and administrative expenses rose to $5.074 million from $4.277 million a year earlier.
• Minor pointNine-month general and administrative expenses rose to $16.318 million in 2026 from $13.942 million in 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Topline data from 400-person sentinel safety cohort and approximately 5,000 patients in main cohort Phase 2b COVID-19 trial anticipated by mid-year 2027

Expanded intellectual property portfolio with new European patent that further protects core IP for Vaxart's oral recombinant norovirus vaccine candidate

Appointed Raquel “Rocky” C. Bono, M.D., Vice Admiral, U.S. Navy (Ret.), a nationally recognized healthcare executive and physician leader to its Board of Directors

Live stockholder fireside chat scheduled for November 6, 2026, at 4:30 p.m. ET

SOUTH SAN FRANCISCO, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) ("Vaxart" or the "Company"), a clinical-stage biotechnology company developing oral recombinant vaccines administered via tablet, today announced its business update and financial results for the third quarter of 2026.

"During the third quarter, the Vaxart team worked diligently to advance our Phase 2b COVID-19 trial," said Steven Lo, Chief Executive Officer of Vaxart. "The release of the topline efficacy and safety data from the main cohort remains a top priority, and we continue to actively work toward completion of analytical testing and disclosure of the trial results, in collaboration with our partner BARDA. In parallel, we continue to reinforce our competitive positioning, recently expanding our global intellectual property portfolio with a key European patent protecting our oral recombinant norovirus vaccine candidate and derivatives thereof. Beyond our clinical work, we remain focused on expanding board governance and fostering open dialogue with our retail stockholders as highlighted by the addition of Dr. Raquel Bono to our Board as Chair of our newly established Stockholder Engagement Committee."

Recent Business Highlights

COVID-19 Program Update

• The Company expects to release topline efficacy and safety data from the complete study, comprising the 400 participants in the sentinel safety cohort and approximately 5,000 participants in the main cohort, by mid-year 2027.
  

BARDA COVID-19 Contract Update

• As of September 30, 2026, Vaxart has received cumulative cash payments of $278.0 million associated with the BARDA contract awarded in 2024.
  

Norovirus Vaccine Developments

• In August 2026, Vaxart announced receipt of a new patent from the European Patent Office for key aspects of Vaxart's room-temperature stable, needle-free pill technology for the use of against norovirus. The patent extends the Company’s intellectual property protection through at least 2036 across major European jurisdictions, including Germany, France, Italy, Spain and the United Kingdom.
  

Influenza Program Developments

• In October 2026, Vaxart announced the publication of positive preclinical study results for its second-generation vaccine candidate, VXA-H5-02, against Highly Pathogenic Avian Influenza (HPAI) H5N1. The results demonstrated complete protection against a fatal dose of the current dominant virus strain.
  

Corporate Governance Enhancements

• In October 2026, the Company announced the appointment of Retired Vice Admiral Raquel C. Bono, M.D., to its Board of Directors. Dr. Bono, a board-certified surgeon and former Director of the Defense Health Agency, brings extensive leadership, public health and governance experience. Dr. Bono was appointed pursuant to the Cooperation Agreement Vaxart entered into with a group of its stockholders in July 2026. She will serve as Chair of the Stockholder Engagement Committee and as a member of the Nominating and Governance Committee and the Clinical and Regulatory Affairs Committee.
  

Financial Results for the Third Quarter Ended September 30, 2026

• Cash, cash equivalents, and short-term investments totaled $65.5 million as of September 30, 2026. Vaxart currently anticipates cash runway into the second quarter of 2027. The Company remains aggressive in exploring various strategies to extend its cash runway through business development partnerships and non-dilutive funding options, with the goal of achieving its upcoming clinical and regulatory milestones and maximizing stockholder value.
• Revenue for the third quarter of 2026 was $10.6 million, compared to $72.4 million for the third quarter of 2025. Revenue in the third quarter of 2026 and the third quarter of 2025 was primarily from government contracts related to the BARDA contract awarded in June 2024, with third quarter 2026 also including revenue recognized from the Dynavax license and collaboration agreement signed in November 2025.
• Research and development expenses were $22.8 million for the third quarter of 2026, compared to $75.9 million for the third quarter of 2025. The decrease is primarily due to a decrease in clinical trial expenses related to our COVID-19 and norovirus vaccine candidates, personnel costs, facilities costs and manufacturing costs.
• General and administrative expenses were $5.1 million for the third quarter of 2026, compared to $4.3 million for the third quarter of 2025. The net increase is primarily due to an increase in professional and legal fees.
• Vaxart reported a net loss of $17.7 million for the third quarter of 2026, compared to a net loss of $8.1 million for the third quarter of 2025. Net loss per share for the third quarter of 2026 was ($0.07), compared to a net loss per share of ($0.04) for the third quarter of 2025.
  

Stockholder Fireside Chat
Vaxart will host a live stockholder fireside chat to answer frequently asked stockholder questions on Friday, November 6, 2026, at 4:30 p.m. ET.

A live webcast of the fireside chat will be available in the Investor section on the Company’s website at www.vaxart.com. Questions may be submitted in advance to ir@vaxart.com.

About Vaxart
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the Company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include pill vaccines designed to protect against coronavirus, norovirus, and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Vaxart’s strategy, prospects, plans and objectives, results and timing of results from preclinical and clinical trials, commercialization agreements and licenses, and beliefs and expectations of management are forward-looking statements, including statements contained in the quotations of Vaxart’s management in this press release. These forward-looking statements may be accompanied by such words as “should,” “believe,” “could,” “potential,” “will,” “expected,” “anticipate,” “plan,” "target," "seek," "intend," "may," "predict," "project," "would," and other words and terms of similar meaning. Examples of such statements include, but are not limited to, statements regarding the potential of VXA-H5-02 and Vaxart’s oral mucosal vaccine platform to induce protective immune responses against H5N1 or other influenza strains in humans; Vaxart’s ability to maintain or extend its intellectual property protection; Vaxart’s ability to develop and commercialize its product candidates; and Vaxart’s expectations regarding the role of its platform in influenza prevention and pandemic preparedness. These forward-looking statements are based on current expectations, estimates, forecasts, and projections about the industry and markets in which Vaxart operates as well as management’s current beliefs and assumptions. Vaxart may not actually achieve the plans, carry out the intentions, or meet the expectations or projections disclosed in the forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations, and projections disclosed in the forward-looking statements, including the possibility that Vaxart’s product candidates may not be approved by the FDA or non-U.S. regulatory authorities; that, even if approved by the FDA or non-U.S. regulatory authorities, Vaxart’s product candidates may not achieve broad market acceptance; and other risks and uncertainties described in the “Risk Factors” sections of Vaxart’s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q filed with the U.S. Securities and Exchange Commission, which are available on the SEC’s website at www.sec.gov. The forward-looking statements in this press release speak only as of the date of this press release. Vaxart undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable law.

Contact
Vaxart Media and Investor Relations:
FINN Partners
IR@vaxart.com

Vaxart, Inc.
Condensed Consolidated Balance Sheets
							September 30,			December 31,
							2026			2025
							(Unaudited)				(1)
							(in thousands)
Assets
	Cash and cash equivalents						$	35,117		$	53,814
	Short-term investments							30,427			9,993
	Accounts receivable							21,027			14,564
	Unbilled receivable from government contracts							9,471			36,781
	Prepaid expenses and other assets							30,959			21,510
	Property and equipment, net							5,008			5,433
	Prepaid clinical services, long-term							-			25,218
	Right-of-use assets, net							9,386			11,432
	Intangible assets, net							2,278			2,826
	Goodwill							4,508			4,508
			Total assets				$	148,181		$	186,079
Liabilities and stockholders’ equity
	Accounts payable						$	29,775		$	21,496
	Deferred government revenue							57			68
	Deferred collaboration revenue							6,322			14,976
	Accrued and other liabilities							33,166			48,696
	Operating lease liability							7,222			8,985
	Liability related to sale of future royalties							5,346			4,060
	Total liabilities							81,888			98,281
	Stockholders’ equity							66,293			87,798
			Total liabilities and stockholders’ equity				$	148,181		$	186,079
(1)			Derived from the audited consolidated financial statements of Vaxart, Inc. for the year ended December 31, 2025, included on the Form 10-K filed with the Securities and Exchange Commission on March 13, 2026.

Vaxart, Inc.
Condensed Consolidated Statements of Operations
(Unaudited)
								QTD							YTD
								Three Months Ended September 30,							Nine Months Ended September 30,
								2026				2025				2026				2025
								( in thousands, except share and per share amounts )
Revenue						$	10,620				$	72,413			$	77,032			$	133,019
	Operating expenses:
		Research and development					22,829					75,947				85,996				156,426
		General and administrative					5,074					4,277				16,318				13,942
Total operating expenses							27,903					80,224				102,314				170,368
Operating loss							(17,283)					(7,811)				(25,282)				(37,349)
	Other expense, net						(94)					(313)				(352)				(1,237)
Loss before income taxes							(17,377)					(8,124)				(25,634)				(38,586)
	Provision for income taxes						312					17				370				132
Net loss						$	(17,689)				$	(8,141)			$	(26,004)			$	(38,718)
Net loss per share, basic and diluted						$	(0.07)				$	(0.04)			$	(0.11)			$	(0.17)
Shares used in computing net income (loss) per share, basic and diluted							243,143,667					228,926,340				241,986,284				228,405,929

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When does Vaxart expect Phase 2b COVID-19 trial results?

Vaxart expects topline efficacy and safety results from the complete Phase 2b COVID-19 study by mid-year 2027. The study comprises 400 participants in the sentinel safety cohort and approximately 5,000 participants in the main cohort.

How much cash does Vaxart have, and how long is its expected runway?

Vaxart had $65.5 million in cash, cash equivalents and short-term investments at September 30, 2026, and expects cash runway into the second quarter of 2027. It is exploring business development partnerships and non-dilutive funding options to extend that runway.